- Home
- LNC vs LEGN Comparison
LNC vs LEGN Comparison
Compare LNC & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LNC | LEGN |
|---|---|---|
| Founded | 1905 | 2014 |
| Country | United States | United States |
| Employees | 9423 | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 5.9B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | LNC | LEGN |
|---|---|---|
| Price | $46.81 | $19.19 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 12 |
| Target Price | $43.13 | ★ $61.33 |
| AVG Volume (30 Days) | 2.1M | ★ 2.3M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.87% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.60 | $42.68 |
| Revenue Next Year | $3.73 | $30.52 |
| P/E Ratio | $7.17 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.18 | $16.24 |
| 52 Week High | $46.82 | $38.42 |
Technical Indicators
Market Signals| Indicator | LNC | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout LNC Lincoln National Corporation
Lincoln National Corp operates multiple insurance and retirement businesses. The company's operating segment includes Annuities; Retirement Plan Services; Life Insurance and Group Protection. Its products include fixed and indexed annuities, variable annuities, universal life insurance (UL), variable universal life insurance (VUL), linked-benefit UL and VUL, indexed universal life insurance (IUL), term life insurance, employer-sponsored retirement plans and services, and group life, disability, and dental.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.